Denali Therapeutics Stock Today

DNLI Stock  USD 16.00  0.60  3.61%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 9

 
High
 
Low
Low
Denali Therapeutics is trading at 16.00 as of the 21st of April 2024. This is a -3.61% down since the beginning of the trading day. The stock's open price was 16.6. Denali Therapeutics has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Denali Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of May 2022 and ending today, the 21st of April 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
8th of December 2017
Category
Healthcare
Classification
Health Care
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. The company has 142.54 M outstanding shares of which 9.41 M shares are currently shorted by private and institutional investors with about 7.82 trading days to cover. More on Denali Therapeutics

Moving together with Denali Stock

  0.75PBH Prestige Brand Holdings Financial Report 2nd of May 2024 PairCorr

Denali Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Denali Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Denali Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEORyan Watts
Thematic IdeaPharmaceutical Products (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Denali Therapeutics report their recommendations after researching Denali Therapeutics' financial statements, talking to executives and customers, or listening in on Denali Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Denali Therapeutics. The Denali consensus assessment is calculated by taking the average forecast from all of the analysts covering Denali Therapeutics.
Financial Strength
Based on the key indicators related to Denali Therapeutics' liquidity, profitability, solvency, and operating efficiency, Denali Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Denali Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.30.2864
Sufficiently Up
Very volatile
Total Current Liabilities121.8 M78 M
Way Up
Slightly volatile
Non Current Liabilities Total42.7 M45 M
Notably Down
Pretty Stable
Total Assets932.8 M1.2 B
Significantly Down
Slightly volatile
Total Current Assets778 M1.1 B
Way Down
Slightly volatile
Denali Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Denali Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Denali Therapeutics' financial leverage. It provides some insight into what part of Denali Therapeutics' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Denali Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Denali Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Denali Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 52.24 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Denali Therapeutics has a current ratio of 3.14, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Denali Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Denali Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Denali Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Denali to invest in growth at high rates of return. When we think about Denali Therapeutics' use of debt, we should always consider it together with cash and equity.

Stock Based Compensation

113.51 Million
Denali Therapeutics (DNLI) is traded on NASDAQ Exchange in USA. It is located in 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 445 people. Denali Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.28 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Denali Therapeutics's market, we take the total number of its shares issued and multiply it by Denali Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Denali Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 142.54 M outstanding shares of which 9.41 M shares are currently shorted by private and institutional investors with about 7.82 trading days to cover. Denali Therapeutics currently holds about 1.07 B in cash with (357.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66.
Check Denali Therapeutics Probability Of Bankruptcy
Ownership Allocation
Denali Therapeutics holds a total of 142.54 Million outstanding shares. The majority of Denali Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Denali Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Denali Therapeutics. Please pay attention to any change in the institutional holdings of Denali Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Denali Ownership Details

Denali Stock Price Odds Analysis

Coming from a normal probability distribution, the odds of Denali Therapeutics jumping above the current price in 90 days from now is about 92.49%. The Denali Therapeutics probability density function shows the probability of Denali Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 3.5369 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Denali Therapeutics will likely underperform. Additionally, denali Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
  Odds Below 16.0HorizonTargetOdds Above 16.0
7.46%90 days
 16.00 
92.49%
Based on a normal probability distribution, the odds of Denali Therapeutics to move above the current price in 90 days from now is about 92.49 (This Denali Therapeutics probability density function shows the probability of Denali Stock to fall within a particular range of prices over 90 days) .

Denali Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Denali Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Denali Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Denali Therapeutics' value.
InstituionRecorded OnShares
T. Rowe Price Associates, Inc.2023-12-31
2.6 M
Bank Of New York Mellon Corp2023-12-31
1.9 M
Marshall Wace Asset Management Ltd2023-12-31
1.7 M
Credit Suisse First Boston (csfb)2023-12-31
1.6 M
Federated Hermes Inc2023-12-31
1.4 M
Casdin Capital, Llc2023-12-31
1.3 M
Gilder Gagnon Howe & Co Llc2023-12-31
1.2 M
Norges Bank2023-12-31
1.2 M
Yiheng Capital Llc2023-12-31
1.2 M
Baillie Gifford & Co Limited.2023-12-31
14.3 M
Blackrock Inc2023-12-31
11.5 M
View Denali Therapeutics Diagnostics

Denali Therapeutics Historical Income Statement

Denali Therapeutics Income Statement is one of the three primary financial statements used for reporting Denali's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Denali Therapeutics revenue and expense. Denali Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Denali Therapeutics' Total Other Income Expense Net is increasing as compared to previous years. The Denali Therapeutics' current Net Interest Income is estimated to increase to about 47.3 M, while Interest Expense is projected to decrease to under 8.6 M. View More Fundamentals

Denali Stock Against Markets

Picking the right benchmark for Denali Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Denali Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Denali Therapeutics is critical whether you are bullish or bearish towards Denali Therapeutics at a given time. Please also check how Denali Therapeutics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Denali Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Pattern Recognition Now

   

Pattern Recognition

Use different Pattern Recognition models to time the market across multiple global exchanges
All  Next Launch Module

Denali Therapeutics Corporate Directors

Denali Therapeutics corporate directors refer to members of a Denali Therapeutics board of directors. The board of directors generally takes responsibility for the Denali Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Denali Therapeutics' board members must vote for the resolution. The Denali Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Peter KleinIndependent DirectorProfile
Douglas ColeIndependent DirectorProfile
Steve KrognesTreasurer DirectorProfile
Jennifer CookIndependent DirectorProfile

How to buy Denali Stock?

Before investing in Denali Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Denali Therapeutics. To buy Denali Therapeutics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Denali Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Denali Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Denali Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Denali Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Denali Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Denali Stock please use our How to Invest in Denali Therapeutics guide.

Already Invested in Denali Therapeutics?

The danger of trading Denali Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Denali Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Denali Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Denali Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for Denali Stock analysis

When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Fundamental Analysis
View fundamental data based on most recent published financial statements
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Is Denali Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.06)
Revenue Per Share
2.406
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.09)
Return On Equity
(0.14)
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.